LIPT - Liraglutide in Polycystic Ovary Syndrome
NCT02073929
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
72
Enrollment
OTHER
Sponsor class
Conditions
Polycystic Ovary Syndrome
Cardiovascular Disease
Interventions
DRUG:
Liraglutide for 26 weeks
DRUG:
placebo
Sponsor
Jens Faber